# Filing Detail

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001612042-26-000005
Filing Date
2026-05-07
Accepted
2026-05-07 07:45:22
Documents
73
Period of Report
2026-03-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 6-K | asnd-20260331.htm iXBRL | 6-K | 2124892
2 | GRAPHIC | img253233243_0.gif | GRAPHIC | 39416
3 | GRAPHIC | img253233243_1.jpg | GRAPHIC | 153848
4 | GRAPHIC | img253233243_2.jpg | GRAPHIC | 136611
5 | GRAPHIC | img253233243_3.jpg | GRAPHIC | 1556460
6 | GRAPHIC | img253233243_4.jpg | GRAPHIC | 523038
7 | GRAPHIC | img253233243_5.jpg | GRAPHIC | 68861
8 | GRAPHIC | img253233243_6.jpg | GRAPHIC | 164115
9 | GRAPHIC | img253233243_7.jpg | GRAPHIC | 192260
10 | GRAPHIC | img253233243_8.jpg | GRAPHIC | 237070
11 | GRAPHIC | img253233243_9.jpg | GRAPHIC | 128430
12 | GRAPHIC | img253233243_10.jpg | GRAPHIC | 61198
13 | GRAPHIC | img253233243_11.jpg | GRAPHIC | 123574
14 | GRAPHIC | img253233243_12.jpg | GRAPHIC | 158877
15 | GRAPHIC | img253233243_13.jpg | GRAPHIC | 151439
16 | GRAPHIC | img253233243_14.jpg | GRAPHIC | 136509
17 | GRAPHIC | img253233243_15.jpg | GRAPHIC | 141051
18 | GRAPHIC | img253233243_16.jpg | GRAPHIC | 28301
19 | GRAPHIC | img253233243_17.jpg | GRAPHIC | 24087
| Complete submission text file | 0001612042-26-000005.txt |  | 17795791

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
20 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | asnd-20260331.xsd | EX-101.SCH | 1260215
76 | EXTRACTED XBRL INSTANCE DOCUMENT | asnd-20260331_htm.xml | XML | 1409010

Mailing Address TUBORG BOULEVARD 12 HELLERUP Denmark
Business Address TUBORG BOULEVARD 12 HELLERUP Denmark 45 70 22 22 44
Ascendis Pharma A/S (Filer) CIK: 0001612042 (see all company filings)

EIN.: 000000000 | State of Incorp.: G7 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-36815 | Film No.: 26950949
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)